1. Home
  2. EAT vs BLTE Comparison

EAT vs BLTE Comparison

Compare EAT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brinker International Inc.

EAT

Brinker International Inc.

HOLD

Current Price

$140.56

Market Cap

5.9B

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$142.79

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAT
BLTE
Founded
1975
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.2B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
EAT
BLTE
Price
$140.56
$142.79
Analyst Decision
Buy
Strong Buy
Analyst Count
21
7
Target Price
$183.00
$198.00
AVG Volume (30 Days)
1.3M
109.8K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
144.71
N/A
EPS
7.90
N/A
Revenue
$5,384,200,000.00
N/A
Revenue This Year
$9.00
N/A
Revenue Next Year
$5.49
$492.11
P/E Ratio
$17.65
N/A
Revenue Growth
21.95
N/A
52 Week Low
$100.30
$56.68
52 Week High
$187.12
$200.00

Technical Indicators

Market Signals
Indicator
EAT
BLTE
Relative Strength Index (RSI) 50.87 39.20
Support Level $131.79 $103.94
Resistance Level $154.23 $172.02
Average True Range (ATR) 6.54 7.26
MACD 0.67 -0.56
Stochastic Oscillator 65.62 34.58

Price Performance

Historical Comparison
EAT
BLTE

About EAT Brinker International Inc.

Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: